Fipco
@fipco.bsky.social
Thoughtful, provocative editorial. Some fair points. Respectfully disagree with apoB/CAC examples. IMO evidence base (including health economics) for these support broader use and are incorporated in some guidelines (apoB: EAS/ESC, CCS, NLA statement) #cardiosky
bsky.app/profile/jame...
bsky.app/profile/jame...
My commentary in JAMA Cardiology - “The Physician–Patient–Podcaster Triangle" - examines how podcasts and social media are transforming the language of medicine and changing how patients understand health, aging, and their relationships with their clinicians. jamanetwork.com/journals/jam...
The Physician–Podcaster–Patient Triangle
This essay discusses physician-podcasters and how their messages can affect the physician-patient relationship.
jamanetwork.com
November 8, 2025 at 2:10 PM
Thoughtful, provocative editorial. Some fair points. Respectfully disagree with apoB/CAC examples. IMO evidence base (including health economics) for these support broader use and are incorporated in some guidelines (apoB: EAS/ESC, CCS, NLA statement) #cardiosky
bsky.app/profile/jame...
bsky.app/profile/jame...
Reposted by Fipco
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure.
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
November 7, 2025 at 8:15 PM
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure.
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
#KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
Reposted by Fipco
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
November 7, 2025 at 4:45 PM
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Reposted by Fipco
The latest empadata dump: @nephroseeker.medsky.social writes up a #NephJC short on the meta analysis
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...
Empagliflozin, the kidney, and what we still don’t understand — NephJC
NephJC short on an empagliflozin meta-analysis
www.nephjc.com
October 21, 2025 at 12:03 AM
The latest empadata dump: @nephroseeker.medsky.social writes up a #NephJC short on the meta analysis
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...
• start prevention earlier (than current guidelines suggest)
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
September 9, 2025 at 9:44 PM
• start prevention earlier (than current guidelines suggest)
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
ICER organization draft: Semaglutide and tirzepatide for obesity are cost effective. For context, a 2014 ACC/AHA task force suggested a less than $50k per QALY threshold as "high value". #cardiosky icer.org/assessment/o...
September 9, 2025 at 6:14 PM
ICER organization draft: Semaglutide and tirzepatide for obesity are cost effective. For context, a 2014 ACC/AHA task force suggested a less than $50k per QALY threshold as "high value". #cardiosky icer.org/assessment/o...
NATURE-Legacy study compares MR/genetically modeled life long LDL-C and blood pressure lowering (HR 0.32) to short term effects in the HOPE-3 trial (HR 0.71). By Brian Ference, et al. /1 #ESCCongress2025 #cardiosky
September 8, 2025 at 1:19 PM
NATURE-Legacy study compares MR/genetically modeled life long LDL-C and blood pressure lowering (HR 0.32) to short term effects in the HOPE-3 trial (HR 0.71). By Brian Ference, et al. /1 #ESCCongress2025 #cardiosky
"This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P." Analysis of UK Biobank data by Elizabeth Epstein, et al. #cardiosky pubmed.ncbi.nlm.nih.gov/40887080/
Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank - PubMed
This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P. Notably, risk was already elevated at as little...
pubmed.ncbi.nlm.nih.gov
September 2, 2025 at 7:02 PM
"This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P." Analysis of UK Biobank data by Elizabeth Epstein, et al. #cardiosky pubmed.ncbi.nlm.nih.gov/40887080/
Statin eligibility with PREVENT vs PCE 10 year risk at various thresholds by Sadiya Kahn, et al.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
August 21, 2025 at 1:02 AM
Statin eligibility with PREVENT vs PCE 10 year risk at various thresholds by Sadiya Kahn, et al.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Lp(a) testing is highly cost effective (cost saving) in this study by Morton, et al. Applies to US and various other countries. #cardiosky #lpa #cea
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis
Cost-effectiveness of Lipoprotein(a) [Lp(a)] testing is not established. We aimed to evaluate the cost-effectiveness of Lp(a) testing in the cardiovas…
www.sciencedirect.com
August 19, 2025 at 11:03 PM
Lp(a) testing is highly cost effective (cost saving) in this study by Morton, et al. Applies to US and various other countries. #cardiosky #lpa #cea
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Somewhat lukewarm view of colchicine in this editorial. "the CLEAR SYNERGY results have brought considerable clinical equipoise for the prescription of colchicine to reduce ASCVD risk" pubmed.ncbi.nlm.nih.gov/40825059/
Colchicine: Evidence to Treat or Equipoise? - PubMed
Colchicine: Evidence to Treat or Equipoise?
pubmed.ncbi.nlm.nih.gov
August 19, 2025 at 5:13 PM
Somewhat lukewarm view of colchicine in this editorial. "the CLEAR SYNERGY results have brought considerable clinical equipoise for the prescription of colchicine to reduce ASCVD risk" pubmed.ncbi.nlm.nih.gov/40825059/
Reposted by Fipco
This "living" guideline document will unlive many people with diabetes if applied.
Why are guideline ppl addicted to sulfunylureas/nsulin/metformin ?
Those are useful to lower A1c from stratospheric levels, but if we are thinking hard outcomes improvement, the answer is #flozin & #glp1
#fail
Why are guideline ppl addicted to sulfunylureas/nsulin/metformin ?
Those are useful to lower A1c from stratospheric levels, but if we are thinking hard outcomes improvement, the answer is #flozin & #glp1
#fail
August 15, 2025 at 12:46 PM
Reposted by Fipco
Orforglipron notches double digit #weightloss investor.lilly.com/news-release...
August 7, 2025 at 11:18 AM
Orforglipron notches double digit #weightloss investor.lilly.com/news-release...
Reposted by Fipco
SURPASS CVOT #T2D #Tirzepatide Non inferior but numerically superior for some endpoints #CVD investor.lilly.com/news-release...
July 31, 2025 at 11:21 AM
SURPASS CVOT #T2D #Tirzepatide Non inferior but numerically superior for some endpoints #CVD investor.lilly.com/news-release...
Looking below the surface... PREVENT equations seem better calibrated vs PCE in other studies compared to recent JACC study. VA, Kaiser, UK Biobank (ex-US), and others. /1
bsky.app/profile/fipc...
bsky.app/profile/fipc...
On the surface, in this dataset of 240k, the PCE calibration seems closer to actual than PREVENT. Excerpt S-Table 45.
bsky.app/profile/pnat...
bsky.app/profile/pnat...
July 19, 2025 at 3:31 PM
Looking below the surface... PREVENT equations seem better calibrated vs PCE in other studies compared to recent JACC study. VA, Kaiser, UK Biobank (ex-US), and others. /1
bsky.app/profile/fipc...
bsky.app/profile/fipc...
On the surface, in this dataset of 240k, the PCE calibration seems closer to actual than PREVENT. Excerpt S-Table 45.
bsky.app/profile/pnat...
bsky.app/profile/pnat...
July 14, 2025 at 5:57 PM
On the surface, in this dataset of 240k, the PCE calibration seems closer to actual than PREVENT. Excerpt S-Table 45.
bsky.app/profile/pnat...
bsky.app/profile/pnat...
In Norway🇳🇴, 4 years after DAPA-HF, 85% of those with reduced ejection fraction heart failure get an SGLT2i. In the US🇺🇸, it's under 30%. #gdmt #flozins #cardiosky
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
July 11, 2025 at 3:43 PM
In Norway🇳🇴, 4 years after DAPA-HF, 85% of those with reduced ejection fraction heart failure get an SGLT2i. In the US🇺🇸, it's under 30%. #gdmt #flozins #cardiosky
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Fipco
A detailed look at dosing, efficacy and tolerability for Amycretin www.thelancet.com/journals/lan... #weightloss #obesity
June 20, 2025 at 11:53 PM
A detailed look at dosing, efficacy and tolerability for Amycretin www.thelancet.com/journals/lan... #weightloss #obesity
Good interview with @danieljdrucker.bsky.social on obesity medicines. I clicked the translate button since hablo muy poco español elpais.com/salud-y-bien...
Daniel Drucker, padre de Ozempic: “No tenemos datos suficientes para usarlo en personas sanas, yo no vendo los fármacos”
El investigador canadiense acaba de recibir el Premio Fronteras del Conocimiento por su papel en los fármacos antiobesidad, aunque es conservador sobre su uso
elpais.com
June 20, 2025 at 6:13 PM
Good interview with @danieljdrucker.bsky.social on obesity medicines. I clicked the translate button since hablo muy poco español elpais.com/salud-y-bien...
Three views on GIP agonism and antagonism. Thread with 3 links. #obesity #cardiosky bsky.app/profile/dani...
As we head to the 2025 @amdiabetesassn.bsky.social GIP biology will be part of the conversation. Here Samms and Sloop summarize the compelling scientific story of Tirzepatide and the case for GIPR co-agonism #Diabetes #Weightloss #obesity diabetesjournals.org/diabetes/art...
June 17, 2025 at 12:38 AM
Three views on GIP agonism and antagonism. Thread with 3 links. #obesity #cardiosky bsky.app/profile/dani...
Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky
www.lipidjournal.com/article/S193...
www.lipidjournal.com/article/S193...
June 11, 2025 at 1:19 AM
Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky
www.lipidjournal.com/article/S193...
www.lipidjournal.com/article/S193...
Mid-sized 🇬🇷discordance study (n=3042, 20 year follow-up) favors apoB over traditional lipid measures. By Giannakopoulou et al. /1 #cardiosky pubmed.ncbi.nlm.nih.gov/40386959/
June 11, 2025 at 1:03 AM
Mid-sized 🇬🇷discordance study (n=3042, 20 year follow-up) favors apoB over traditional lipid measures. By Giannakopoulou et al. /1 #cardiosky pubmed.ncbi.nlm.nih.gov/40386959/
Merck's enlicitide, an oral PCSK9i, meets LDL-C and other endpoints in 2 phase 3 trials. Details to come. "There were no clinically meaningful differences in incidences of AEs and SAEs in either trial" #cardiosky
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
June 9, 2025 at 1:03 PM
Merck's enlicitide, an oral PCSK9i, meets LDL-C and other endpoints in 2 phase 3 trials. Details to come. "There were no clinically meaningful differences in incidences of AEs and SAEs in either trial" #cardiosky
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
Pooled Cohort Equations and newer PREVENT 10 year risk equations won't identify many of those who had early MIs. #cardiosky pmc.ncbi.nlm.nih.gov/articles/PMC...
Performance of PREVENT equations for cardiovascular risk prediction in young patients with myocardial infarction: From the MGB YOUNG-MI registry
Predicting cardiovascular risk in young adults remains challenging. The newly developed PREVENT equations offers several advantages for short and long-term cardiovascular risk prediction. To determine...
pmc.ncbi.nlm.nih.gov
May 29, 2025 at 3:31 AM
Pooled Cohort Equations and newer PREVENT 10 year risk equations won't identify many of those who had early MIs. #cardiosky pmc.ncbi.nlm.nih.gov/articles/PMC...